艾易舒注射液联合化疗对原发性肝癌治疗的Meta分析  

Meta-analysis of Aiyishu injection combined chemotherapy for the treatment of liver cancer

作　　者：王云锋[1] 杨兴华[1] 刘芬[1] 于飞[2] 

机构地区：[1]首都医科大学公共卫生学院临床流行病学北京市重点实验室,北京100069 [2]首都医科大学中医药学院

出　　处：《中国预防医学杂志》2016年第4期292-298,共7页Chinese Preventive Medicine

摘　　要：目的系统评价艾易舒注射液联合化疗对肝癌的辅助治疗效果与安全性。方法计算机检索Cochrane图书馆、Medline、EMbase、CBM、CNKI、维普、万方等数据库,时限从建库至2014年4月,查找国内外关于艾易舒注射液联合化疗或肝动脉化疗栓塞术治疗（TACE）原发性肝癌的临床对照试验。按照纳入与排除标准选择文献、提取资料、评价质量后,利用Revman 5.2软件进行Meta分析。结果最终纳入13个RCT研究,共864例患者。Meta分析结果显示,与对照组相比,艾易舒注射液联合化疗或TACE干预组在提高治疗有效率（RR=1.60,95%CI：1.08-2.39）;临床受益率（RR=1.23,95%CI：1.06-1.43）;生活质量改善率（RR=2.05,95%CI：1.63-2.58）;临床症状改善率（RR=1.37,95%CI：1.06-1.77）;Ⅱ度以上白细胞下降发生率（RR=0.27,95%CI：0.13-0.56）上差异均有统计学意义。但在降低消化道症状发生率（RR=0.66,95%CI：0.43-1.01）;降低化疗药物使用中的肝功能下降发生率（RR=0.65,95%CI：0.35-1.21）上差异尚无统计学意义。结论艾易舒注射液辅助肝癌治疗中具有治疗有效性及安全性,不仅可提高临床治疗的有效率和受益率,而且能改善患者的生活质量和临床症状,减轻化疗方案引起的骨髓抑制,但对消化道症状等不良反应未显示出明显效果。Objective To evaluate the effectiveness and safety of the Aiyishu injection combined chemotherapy in the adjuvant therapy of liver cancer. Methods All case-control clinical trial data on Aiyishu injection combined chemotherapy or TACE in the treatment of primary liver cancer were retrieved from database of Cochrane library,Medline,EMbase,CBM,CNKI and others up to April 2014.Literatures were chosen according to including and excluding standard.RevMan 5.2software was used for Meta-analysis. Results Thirteen randomized clinical trials with 864 patients were included.Meta-analysis revealed that,compared with control group,Aiyishu combined chemotherapy or TACE produced a statistically significant improvement for a higher effective rate（RR= 1.60,95%CI：1.08-2.39）,clinical beneficial rate（RR=1.23,95%CI：1.06-1.43）and quality of life（RR=2.05,95%CI：1.63-2.58）,while effectively relieved clinical symptoms（RR=1.37,95%CI：1.06-1.77）and prevented the decline of WBC count（RR=0.27,95%CI：0.13-0.56）.However,there was no statistical significance on reducing the incidence of gastrointestinal symptoms（RR=0.66,95%CI：0.43-1.01）and the incidence of liver function damage during chemotherapy（RR=0.65,95%CI：0.35-1.21）. Conclusions Aiyishu injection combined chemotherapy is proved to be an effective and safe way to treat liver cancer,not only by producing higher clinical effective rate and beneficial rate,but also by improving patient′s quality of life,relieving clinical symptoms and bone marrow suppression.

关 键 词：艾易舒注射液 肝癌 随机对照试验 META分析 

分 类 号：R735.7[医药卫生—肿瘤]